Yuhan Corporation
000100
주식 순위
#3832
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
주가
$63.22
시가총액
$4.27B
변동 (1일)
-3.12%
변동 (1년)
-23.57%
국가
KR
거래 Yuhan Corporation (000100)
카테고리
Healthcare
Yuhan Corporation (000100)의 수익
Jun 2026 기준 수익 TTM: $205.87M
Yuhan Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익은 $205.87M입니다. 2024년에 회사는 $41.79M의 수익을 올렸으며 이는 2023년의 수익 $104.14M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Yuhan Corporation의 수익 기록 (2007 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $205.87M | 33.56% |
| 2025 | $154.14M | 268.88% |
| 2024 | $41.79M | -59.88% |
| 2023 | $104.14M | 38.44% |
| 2022 | $75.22M | -29.06% |
| 2021 | $106.03M | -52.01% |
| 2020 | $220.97M | 364.61% |
| 2019 | $47.56M | -40.76% |
| 2018 | $80.28M | -40.96% |
| 2017 | $135.98M | -19.98% |
| 2016 | $169.93M | 18.62% |
| 2015 | $143.25M | 35.02% |
| 2014 | $106.09M | 4.27% |
| 2013 | $101.75M | 1.19% |
| 2012 | $100.55M | 9.06% |
| 2011 | $92.20M | -27.70% |
| 2010 | $127.53M | 8.26% |
| 2009 | $117.80M | 4.84% |
| 2008 | $112.36M | 0.30% |
| 2007 | $112.02M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $3.62B | 1,657.37% |
DE
|
|
| $3.40B | 1,553.97% |
DE
|
|
| $1.72B | 737.24% |
JP
|
|
| $930.30M | 351.89% |
CH
|
|
| $1.69B | 722.21% |
IN
|
